WORCESTER, Mass., Oct. 16, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has commenced the enrollment of subjects in the company's bioequivalency clinical trial of MetControl(tm), the company's proprietary Metformin medicinal chewing gum product. A study is currently being conducted in the US wherein the site is actively screening and enrolling subjects. The protocol for the study is an open-label, two-treatment, two-period, randomized, crossover study comparing MetControl(tm) and immediate release Metformin tablets in healthy volunteers. The study results will allow the company to proceed with additional R&D initiatives and consider regulatory agency registration applications.
